ascopubs.org

Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study.

Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a ...
EurekAlert!

Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy

Barcelona, Spain, 30 September 2019 - Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the ...
The Globe and Mail

NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update, NovoCure Ltd.
ascopubs.org

Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study.

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients ...